AR and neoplasm: The total number of identified AR binding events greatly varied between the tumor samples (Appendix Table S4), which is consistent with previous nuclear receptor ChIP-seq in prostate and breast tumor samples (Ross-Innes et al, 2012; Jansen et al, 2013; Sharma et al, 2013).